Hepatocellular Carcinoma

Key clinical point: Androgen receptor inhibitors (ARIs) improve survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC) regardless of age. Older patients (age, 80 years and above) experience higher rates of high-grade and serious adverse events.

Major finding: ARIs vs placebo improved overall survival in older (adjusted hazard ratio [aHR], 0.79; 95% confidence interval [CI], 0.64-0.98) and younger patients (aHR, 0.69; 95% CI, 0.60-0.80). ARIs also improved metastasis-free survival in older (aHR, 0.37; 95% CI, 0.28-0.47) and younger patients (aHR, 0.31; 95% CI, 0.27-0.35). Patients who received ARIs vs placebo experienced higher rates of adverse events.

Study details: A pooled analysis of 3 randomized trials including patients with nonmetastatic CRPC randomly assigned to receive ARI (apalutamide, enzalutamide, or darolutamide; n=2,694) or placebo (n=1,423).

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Fallah J et al. Lancet Oncol. 2021 Jul 23. doi: 10.1016/S1470-2045(21)00334-X.

Key clinical point: Androgen receptor inhibitors (ARIs) improve survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC) regardless of age. Older patients (age, 80 years and above) experience higher rates of high-grade and serious adverse events.

Major finding: ARIs vs placebo improved overall survival in older (adjusted hazard ratio [aHR], 0.79; 95% confidence interval [CI], 0.64-0.98) and younger patients (aHR, 0.69; 95% CI, 0.60-0.80). ARIs also improved metastasis-free survival in older (aHR, 0.37; 95% CI, 0.28-0.47) and younger patients (aHR, 0.31; 95% CI, 0.27-0.35). Patients who received ARIs vs placebo experienced higher rates of adverse events.

Study details: A pooled analysis of 3 randomized trials including patients with nonmetastatic CRPC randomly assigned to receive ARI (apalutamide, enzalutamide, or darolutamide; n=2,694) or placebo (n=1,423).

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Fallah J et al. Lancet Oncol. 2021 Jul 23. doi: 10.1016/S1470-2045(21)00334-X.

Key clinical point: Androgen receptor inhibitors (ARIs) improve survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC) regardless of age. Older patients (age, 80 years and above) experience higher rates of high-grade and serious adverse events.

Major finding: ARIs vs placebo improved overall survival in older (adjusted hazard ratio [aHR], 0.79; 95% confidence interval [CI], 0.64-0.98) and younger patients (aHR, 0.69; 95% CI, 0.60-0.80). ARIs also improved metastasis-free survival in older (aHR, 0.37; 95% CI, 0.28-0.47) and younger patients (aHR, 0.31; 95% CI, 0.27-0.35). Patients who received ARIs vs placebo experienced higher rates of adverse events.

Study details: A pooled analysis of 3 randomized trials including patients with nonmetastatic CRPC randomly assigned to receive ARI (apalutamide, enzalutamide, or darolutamide; n=2,694) or placebo (n=1,423).

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Fallah J et al. Lancet Oncol. 2021 Jul 23. doi: 10.1016/S1470-2045(21)00334-X.

Key clinical point: In asymptomatic patients with nonmetastatic castration-resistant prostate cancer (CRPC), darolutamide vs placebo maintains health-related quality of life (QoL).

Major finding: Darolutamide vs placebo significantly delayed time to deterioration of Functional Assessment of Cancer Therapy-Prostate cancer subscale (hazard ratio [HR], 0.80; P = .0005), urinary symptoms (HR, 0.64; P < .0001), and bowel symptoms (HR, 0.78; P = .0027).

Study details: A study of patient-reported health-related QoL from randomized, double-blind, placebo-controlled, phase 3 ARAMIS trial, which evaluated 1,509 patients with nonmetastatic CRPC and prostate-specific antigen doubling time of 10 months or less who were randomly assigned 2:1 to receive darolutamide or placebo while continuing androgen deprivation therapy.

Disclosures: This study was funded by Bayer AG and Orion Pharma. The authors received grants, personal fees, and/or nonfinancial support from various sources. Some authors were employees of pharmaceutical companies.

Source: Smith MR. Eur J Cancer. 2021 Jul 14. doi: 10.1016/j.ejca.2021.06.010.

Key clinical point: In asymptomatic patients with nonmetastatic castration-resistant prostate cancer (CRPC), darolutamide vs placebo maintains health-related quality of life (QoL).

Major finding: Darolutamide vs placebo significantly delayed time to deterioration of Functional Assessment of Cancer Therapy-Prostate cancer subscale (hazard ratio [HR], 0.80; P = .0005), urinary symptoms (HR, 0.64; P < .0001), and bowel symptoms (HR, 0.78; P = .0027).

Study details: A study of patient-reported health-related QoL from randomized, double-blind, placebo-controlled, phase 3 ARAMIS trial, which evaluated 1,509 patients with nonmetastatic CRPC and prostate-specific antigen doubling time of 10 months or less who were randomly assigned 2:1 to receive darolutamide or placebo while continuing androgen deprivation therapy.

Disclosures: This study was funded by Bayer AG and Orion Pharma. The authors received grants, personal fees, and/or nonfinancial support from various sources. Some authors were employees of pharmaceutical companies.

Source: Smith MR. Eur J Cancer. 2021 Jul 14. doi: 10.1016/j.ejca.2021.06.010.

Key clinical point: In asymptomatic patients with nonmetastatic castration-resistant prostate cancer (CRPC), darolutamide vs placebo maintains health-related quality of life (QoL).

Major finding: Darolutamide vs placebo significantly delayed time to deterioration of Functional Assessment of Cancer Therapy-Prostate cancer subscale (hazard ratio [HR], 0.80; P = .0005), urinary symptoms (HR, 0.64; P < .0001), and bowel symptoms (HR, 0.78; P = .0027).

Study details: A study of patient-reported health-related QoL from randomized, double-blind, placebo-controlled, phase 3 ARAMIS trial, which evaluated 1,509 patients with nonmetastatic CRPC and prostate-specific antigen doubling time of 10 months or less who were randomly assigned 2:1 to receive darolutamide or placebo while continuing androgen deprivation therapy.

Disclosures: This study was funded by Bayer AG and Orion Pharma. The authors received grants, personal fees, and/or nonfinancial support from various sources. Some authors were employees of pharmaceutical companies.

Source: Smith MR. Eur J Cancer. 2021 Jul 14. doi: 10.1016/j.ejca.2021.06.010.

Key clinical point: Cabazitaxel improves radiographic progression-free survival (rPFS) in older (age, 70 years and above) and younger (age, less than 70 years) patients with metastatic castration-resistant prostate cancer (CRPC) vs abiraterone or enzalutamide.

Major finding: The median rPFS significantly improved with cabazitaxel vs abiraterone/enzalutamide in older (hazard ratio [HR], 0.58; P = .012) and younger patients (HR, 0.47; P < .001). There was no significant improvement in overall survival with cabazitaxel in older (P = .084) and younger patients (P = .093).

Study details: An open-label, randomized CARD study of 255 patients with metastatic CRPC randomly assigned to either cabazitaxel plus prednisone and granulocyte colony-stimulating factor or enzalutamide/abiraterone+prednisone.

Disclosures: The study was funded by Sanofi. The authors reported grants or funding, honoraria, consulting/advisory fees, royalties, patents, employment/affiliation, and/or stock ownership/options.

Source: Sternberg CN et al. Eur Urol. 2021 Jul 14. doi: 10.1016/j.eururo.2021.06.021.

Key clinical point: Cabazitaxel improves radiographic progression-free survival (rPFS) in older (age, 70 years and above) and younger (age, less than 70 years) patients with metastatic castration-resistant prostate cancer (CRPC) vs abiraterone or enzalutamide.

Major finding: The median rPFS significantly improved with cabazitaxel vs abiraterone/enzalutamide in older (hazard ratio [HR], 0.58; P = .012) and younger patients (HR, 0.47; P < .001). There was no significant improvement in overall survival with cabazitaxel in older (P = .084) and younger patients (P = .093).

Study details: An open-label, randomized CARD study of 255 patients with metastatic CRPC randomly assigned to either cabazitaxel plus prednisone and granulocyte colony-stimulating factor or enzalutamide/abiraterone+prednisone.

Disclosures: The study was funded by Sanofi. The authors reported grants or funding, honoraria, consulting/advisory fees, royalties, patents, employment/affiliation, and/or stock ownership/options.

Source: Sternberg CN et al. Eur Urol. 2021 Jul 14. doi: 10.1016/j.eururo.2021.06.021.

Key clinical point: Cabazitaxel improves radiographic progression-free survival (rPFS) in older (age, 70 years and above) and younger (age, less than 70 years) patients with metastatic castration-resistant prostate cancer (CRPC) vs abiraterone or enzalutamide.

Major finding: The median rPFS significantly improved with cabazitaxel vs abiraterone/enzalutamide in older (hazard ratio [HR], 0.58; P = .012) and younger patients (HR, 0.47; P < .001). There was no significant improvement in overall survival with cabazitaxel in older (P = .084) and younger patients (P = .093).

Study details: An open-label, randomized CARD study of 255 patients with metastatic CRPC randomly assigned to either cabazitaxel plus prednisone and granulocyte colony-stimulating factor or enzalutamide/abiraterone+prednisone.

Disclosures: The study was funded by Sanofi. The authors reported grants or funding, honoraria, consulting/advisory fees, royalties, patents, employment/affiliation, and/or stock ownership/options.

Source: Sternberg CN et al. Eur Urol. 2021 Jul 14. doi: 10.1016/j.eururo.2021.06.021.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659. 

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659. 

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.